Practical considerations for biosimilars: substitution, interchange and formulary selection
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Presentation
- By: VULTO, Arnold (Erasmus University Medical Center, Hopsital Pharmacy, Rotterdam, Netherlands)
- Co-author(s): Arnold Vulto
Europe has taken the lead in policies for development, licensing and implementation of biosimilars since 2004. In the past 11 years the European Commission, on the recommendation of the European Medicines Agency, has approved 28 biosimilars in 3 different classes Many countries with advanced drug licensing systems have followed the standards.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.